Valeant Buys Again With Another Acquisition In Eastern EuropeMarch 2012 | Industry Trend Analysis
BMI View: Valeant remains firmly on the acquisition trail and has once again boosted its exposure to Eastern Europe with a particular focus on Russia. BMI's positive view on the attractiveness of this region, particularly of the over-the-counter (OTC) pharmaceuticals market, matches Valeant's. This sector of the drug market remains fragmented, though the Canadian firm's latest acquisition will be competing with another recently arrived, Western-backed, cough and cold branded drugmaker in the form of Johnson & Johnson (J&J), which is selling OTC brands previosuly owned by Russian firm J.B. Chemicals & Pharmaceuticals.
To read the full article, please choose one of the following options: